Country: Canada
Language: English
Source: Health Canada
ATAZANAVIR (ATAZANAVIR SULFATE)
MYLAN PHARMACEUTICALS ULC
J05AE08
ATAZANAVIR
300MG
CAPSULE
ATAZANAVIR (ATAZANAVIR SULFATE) 300MG
ORAL
30
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0149741004; AHFS:
APPROVED
2017-04-18
_ _ _Page 1 of 81_ PRODUCT MONOGRAPH Pr MYLAN-ATAZANAVIR atazanavir sulfate capsules 150 mg, 200 mg and 300 mg atazanavir Azapeptide Inhibitor of HIV-1 Protease Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Date of Revision: May 19, 2021 Submission Control No: 251525 _ _ _Page 2 of 81 _ _ _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ............................................................................................ 4 WARNINGS AND PRECAUTIONS ............................................................................ 5 ADVERSE REACTIONS............................................................................................12 DRUG INTERACTIONS ............................................................................................24 DOSAGE AND ADMINISTRATION .........................................................................40 OVERDOSAGE .........................................................................................................42 ACTION AND CLINICAL PHARMACOLOGY.........................................................43 STORAGE AND STABILITY ....................................................................................48 DOSAGE FORMS, COMPOSITION AND PACKAGING ..........................................48 PART II: SCIENTIFIC INFORMATION .......................................................................... 50 PHARMACEUTICAL INFORMATION .....................................................................50 CLINICAL TRIALS ...................................................................................................52 DETAILED PHARMACOLOGY................................................................................58 MICROBIOLOGY .......................... Read the complete document